Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.
Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.2 which represents a decrease of $-1.82 or -15.14% from the prior close of $12.02. The stock opened at $11.24 and touched a ...
2d
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO ...
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback